Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe Gulf-region specialist GAIA Healthcare FZ LLC obtains license for the marketing of Carragelose nasal sprays Expansion of Carragelose partner network in Eastern Europe with VitaPlus Kft. Korneuburg, Austria, 26 March 2024 – Marinomed Biotech AG [ … ]

Marinomed Biotech AG: Lucia Ziegler new Head of Investor & Public Relations Korneuburg, Austria, 1 March 2024 – Lucia Ziegler will take over the newly integrated "Investor & Public Relations" department at Marinomed Biotech AG (VSE:MARI) as of the beginning of March 2024. In addition to her previous PR tasks, Lucia Ziegler will also be res [ … ]

 Marinomed Biotech AG announces preliminary revenue for 2023 Preliminary revenues eased as expected to € 9.2 m in 2023 (2022: € 11.3 m) due to reduced Carragelose order volumes caused by sufficient customer stock levels Cash position at € 2.6 m; financial stability secured by cost-conscious cash management and convertible note funding program O [ … ]

Marinomed Biotech AG with important progress for Carragelose in 2024 First patient enrolled in clinical study investigating the moisturizing effectiveness of Carragelose eye drops Clinical data showing the effectiveness of Carragelose in alleviating allergic symptoms in patients with grass pollen allergy published in peer-reviewed International J [ … ]